Rimegepant for acute vestibular migraine in adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional Phase 4 trial evaluates the acute effects of rimegepant on vestibular migraine symptoms. Participants receive alternating active and placebo dosing to assess the medication’s ability to reduce vestibular symptoms and related discomfort during attacks. Eligible adults with a defined history of vestibular migraine will be followed to compare responses between treatment sequences. Safety monitoring includes typical hepatic, renal, cardiovascular, and other exclusion criteria to ensure participant well-being. The study is led by Wensheng Qu and conducted at Tongji Hospital and affiliated centers in Wuhan, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18-60 years, male or female.
2. Diagnosis of vestibular migraine according to the Bárány Society criteria.
3. ≥4 episodes of characteristic vestibular symptoms in the past year, each of moderate to severe intensity and lasting \>2 hours (without intervention).
4. Signed informed consent obtained from the participant.

Exclusion Criteria:

1. Presence of other disorders causing acute vestibular symptoms (e.g., Ménière's disease, otitis media).
2. Coexisting non-vertiginous dizziness (e.g., dizziness due to panic disorder), unless the patient can clearly distinguish these episodes from vestibular-migraine attacks.
3. Severe hepatic dysfunction (ALT and/or AST \>3× upper limit of normal) or renal impairment (creatinine clearance \<30 mL/min).
4. Severe cardiovascular or cerebrovascular disease.
5. Alcohol abuse or substance abuse.
6. Known pregnancy or lactation, or a positive pregnancy test prior to randomization.
7. Contraindication or hypersensitivity to any medications used in the study.
8. Initiation or dose adjustment of any preventive migraine therapy within 3 months prior to study drug administration.
9. Use of any other anti-vertigo or analgesic medication within 6 hours before study drug administration.
10. Participation in another interventional clinical study that could affect outcome assessment.
11. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study or poses significant risk.

Where it's running

• Tongji Hospital
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: Wensheng Qu
• Email: qws0309@163.com
• Phone: 18971622660

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Genetic and blood markers linked to Menière's disease and symptoms

  This project will test whether common gene variants and blood markers that control inner-ear ion balance differ between people with Menière's disease, people with vestibular migraine, and people without vestibular disorders.

  Recruiting IRCCS San Raffaele · Milan, Italy · NCT07518069

• Virtual Reality and Biofeedback for Adolescents with Chronic Dizziness

  This study tests a virtual reality and biofeedback approach to help adolescents with chronic dizziness from PPPD or vestibular migraine see if it can reduce symptoms and improve daily function.

  Recruiting Early Phase 1 Boston Children's Hospital · Waltham, Massachusetts · NCT07374640

• International Headache Registry

  This study is collecting information from people aged 4 to 99 who have headaches or related conditions to see how these issues affect their health and treatment over time.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT05418218

• Registry for headache and vertigo conditions in China

  This study is collecting information from people of all ages who have headaches or vertigo to see how different treatments work and how these conditions relate to other health issues.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT04939922

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.